Peginterferon Alfa-2a for AIDS-associated kaposi sarcoma: Experience with 10 patients
Clinical Infectious Diseases , Volume 57 - Issue 10 p. 1497- 1499
In this observational cohort study, 10 patients with extensive or treatment-refractory AIDS-associated Kaposi sarcoma were treated with peginterferon alfa-2a. Tumor responses were observed in 9 patients with a median progression-free survival of 645 days. Peginterferon alfa-2a could be an effective therapy for extensive or treatment-resistant Kaposi sarcoma.
|Highly active antire-troviral therapy, HIV/AIDS, Kaposi sarcoma, Peginterferon alfa-2a, Treatment effectiveness|
|Clinical Infectious Diseases|
|Organisation||Department of Internal Medicine|
Rokx, C, van der Ende, M.E, Verbon, A, & Rijnders, B.J.A. (2013). Peginterferon Alfa-2a for AIDS-associated kaposi sarcoma: Experience with 10 patients. Clinical Infectious Diseases, 57(10), 1497–1499. doi:10.1093/cid/cit517